The factory will be expanded to produce the pills for all markets outside the US, according to CEO Mike Doustdar. Production of the pill for the US market will take place in the US, according to the company.
The Wegovy pill is seen as a crucial launch for Novo Nordisk, which has lost market share to, among others, Eli Lilly's Zepbound in injectable weight-loss preparations.
Doustdar's announcement about the Novo Nordisk venture in Ireland comes after an unexpectedly weak sales forecast for 2026, which was presented last week.
